DE69722608D1 - Hsv-mutant-1716 zur behandlung von mesotheliomen - Google Patents

Hsv-mutant-1716 zur behandlung von mesotheliomen

Info

Publication number
DE69722608D1
DE69722608D1 DE69722608T DE69722608T DE69722608D1 DE 69722608 D1 DE69722608 D1 DE 69722608D1 DE 69722608 T DE69722608 T DE 69722608T DE 69722608 T DE69722608 T DE 69722608T DE 69722608 D1 DE69722608 D1 DE 69722608D1
Authority
DE
Germany
Prior art keywords
mutant
mesotheliomas
hsv
treating
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69722608T
Other languages
English (en)
Other versions
DE69722608T2 (de
Inventor
Susanne Moira Brown
Alasdair Roderick Maclean
Nigel William Fraser
Bruce Paul Randazzo
Steven Albelda
Larry Kaiser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Wistar Institute of Anatomy and Biology
Original Assignee
University of Glasgow
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9601507.8A external-priority patent/GB9601507D0/en
Priority claimed from GBGB9623365.5A external-priority patent/GB9623365D0/en
Application filed by University of Glasgow, Wistar Institute of Anatomy and Biology filed Critical University of Glasgow
Application granted granted Critical
Publication of DE69722608D1 publication Critical patent/DE69722608D1/de
Publication of DE69722608T2 publication Critical patent/DE69722608T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
DE69722608T 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen Expired - Lifetime DE69722608T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9601507.8A GB9601507D0 (en) 1996-01-25 1996-01-25 Treatment of non-neuronal cancer using HSV mutant
GB9601507 1996-01-25
GB9623365 1996-11-09
GBGB9623365.5A GB9623365D0 (en) 1996-11-09 1996-11-09 Non-neuronal cancer treatment
PCT/GB1997/000232 WO1997026904A1 (en) 1996-01-25 1997-01-27 Treatment of non-neuronal cancer using hsv mutant

Publications (2)

Publication Number Publication Date
DE69722608D1 true DE69722608D1 (de) 2003-07-10
DE69722608T2 DE69722608T2 (de) 2004-04-29

Family

ID=26308525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722608T Expired - Lifetime DE69722608T2 (de) 1996-01-25 1997-01-27 Hsv-mutant-1716 zur behandlung von mesotheliomen

Country Status (6)

Country Link
US (3) US20050226850A1 (de)
EP (2) EP0895476B1 (de)
AT (1) ATE241994T1 (de)
AU (1) AU1550797A (de)
DE (1) DE69722608T2 (de)
WO (1) WO1997026904A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
EP1061806A4 (de) * 1998-03-12 2001-09-12 Univ Pennsylvania Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen
DE60039730D1 (de) * 1999-02-05 2008-09-11 Arch Dev Corp Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
MXPA01010393A (es) 1999-04-15 2004-04-02 Pro Virus Inc Tratamiento de neoplasmas con virus.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2260057T3 (es) 1999-09-17 2006-11-01 Wellstat Biologics Corporation Virus oncolitico.
KR100768408B1 (ko) 2000-01-21 2007-10-18 바이오벡스 리미티드 헤르페스 바이러스 주
CA2517147C (en) 2003-03-07 2011-06-14 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
CA2520279C (en) 2003-03-27 2012-09-04 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US20070003520A1 (en) 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
CN102357104B (zh) 2005-03-07 2016-01-27 罗巴斯研究机构 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
CA2611563C (en) 2005-05-03 2013-04-23 The University Of Western Ontario An oral device and kit for use in association therewith
US8481023B2 (en) 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
AU2009237353B2 (en) 2008-04-15 2014-10-23 Trudell Medical International Swallowing air pulse therapy mouthpiece and method for the use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
DE69332525T2 (de) * 1992-03-31 2003-04-17 Arch Dev Corp Behandlung von Tumorerkrankungen mit modifiziertem HSV
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6139834A (en) * 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5728379A (en) * 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0862445B2 (de) * 1995-10-06 2017-03-22 Arch Development Corporation Kombination von Herpes simplex Virus und Chemotherapie für Krebstherapie
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen

Also Published As

Publication number Publication date
US20110195053A1 (en) 2011-08-11
AU1550797A (en) 1997-08-20
DE69722608T2 (de) 2004-04-29
US20070292394A1 (en) 2007-12-20
EP0895476A1 (de) 1999-02-10
ATE241994T1 (de) 2003-06-15
EP0895476B1 (de) 2003-06-04
WO1997026904A1 (en) 1997-07-31
EP1314430A1 (de) 2003-05-28
US20050226850A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
DE69722608D1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
NO20003230D0 (no) Inhibering av RAF-kinase ved anvendelse av symmetrisk og usymmetrisk substituerte difenylureaforbindelser
DE69425267T2 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69332831T2 (de) Rekombinanter schweinepocken-virus
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE402713T1 (de) Genetisch manipulierte herpesviren zur behandlung von tumoren
ATE219681T1 (de) Behandlung von krebs durch verwendung von hsv- mutanten
DE69415522T2 (de) Aromatische inhibitoren von acetylcholinesterase
NO20002504L (no) Adenovirusvektorer og fremgangsmÕte for Õ redusere homologe rekombinasjonsfenomener
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
ATE152725T1 (de) Silylierte acetylcholinesterase inhibitoren
DE69433978D1 (de) Methode der spezifischen abschaltung von genen durch dna-methylierung
DE69816751D1 (de) Materialien zur behandlung des glaukoms
AU2003234342A8 (en) Ablated slam-dependent entry
ATE178654T1 (de) Impstoff zum schutze von pferden gegen pferdeherpesvirus-infektionen
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE130868T1 (de) Verwendung von mischungen von mannich-acrylamid- polymeren und dimethyldiallylammoniumhalidpolymeren zur ausflockung von enzymbrühen.
ATE184893T1 (de) Verwendung von enaminen als vulkanisationsbeschleuniger
DE69409961T2 (de) Triarylethylenderivate zur therapeutischen verwendung
ATE9579T1 (de) Substituierte benzonitrile und zusammensetzungen zum hemmen von viren.
DE69802828D1 (de) Verwendung von 6,7-substituierter 2-aminotetraline zur behandlung von zytokin-vermittleten entzündungszuständen
DE69711422T2 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE25530T1 (de) Polymerisierbare massen und verwendung von arylaminen als haertungsbeschleuniger hierfuer.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition